Scientific Pillars & Consortium Structure

Integrated infrastructure designed for end-to-end translational impact

COPATHOS coordinates discovery, biomarker development, neuropathological validation, and regulatory deployment within a single framework for overlapping neurological disease states — including coexisting Alzheimer's, Parkinson's, frontotemporal dementias, and cerebrovascular and cardiometabolic disease.

Research Projects

First projects underway

Starting point 1

Where do chronic and acute brain pathologies meet?

Where it is becoming clear that tauopathies can involve the intersection of multiple chronic pathologies, such as Alzheimer's disease, CTE and Frontotemporal dementias—each contributing different predominant forms of pathological tau, it is less clear how varied synuclein pathologies differ. Efforts are underway to better understand how protein signatures change with the impact of other brain injuries to accelerate or alter the disease process in dementias. Granular protein profiling technologies are helping us to establish signatures of disease burden across different forms of pathological proteins and comorbidities (co-occuring health conditions).

Starting point 2

Differences in proteoforms in synucleinopathies

Targeted protein sequencing of donated frozen brain specimens is being performed in synucleinopathies to firmly establish differences in synuclein protein modifications in well-characterized, diseased individuals by mass spectrometry and novel antibodies to more comprehensively understand disease states and progression. Studies aim to understand the varied forms of synucleins in health and disease and the impact of other types of brain injury such as TIAs and other closed head injuries that may accrue over a lifetime. Knowing which protein forms are present in Alzheimer's disease compared to Lewy body dementias and Parkinson's disease, will help us better understand subtypes with multipathology burden and how best to treat these diseases. These studies are essential for more effective clinical trials in the future.

Leadership Integration

The translational pipeline: end-to-end coverage

  1. CC

    Stage 1

    Gene Discovery & Multi-Omic Profiling

    Carlos Cruchaga, PhD

    Neurogenomics & Multi-Omic Integration

  2. TK

    Stage 2

    Fluid Biomarker Development & Validation

    Thomas K. Karikari, PhD

    Fluid Biomarker Innovation

  3. RR

    Stage 3

    Neuropathological Ground Truth & Clinical Trial Validation

    Robert A. Rissman, PhD

    Biomarker Validation & Translational Pathology

  4. TV

    Stage 4

    Assay Standardization, Regulatory Strategy & Deployment

    Timothy E. Van Meter, PhD

    Diagnostic Technology & Consortium Operations

Together, COPATHOS leadership covers the complete translational arc from molecular target identification to clinical diagnostic deployment.

Consortium Programs

Where leadership expertise is applied

Systems Biology & Multi-Omics Architecture Program

Carlos Cruchaga, PhD

Integrates genetic, proteomic, lipidomic, and transcriptomic signals into mechanistically grounded diagnostic panels and therapeutic-target maps.

Fluid Biomarker Development & Clinical Implementation Program

Thomas K. Karikari, PhD

Advances next-generation assays that distinguish overlapping disease processes and support risk stratification and treatment optimization.

Clinical Biomarker Integration & Trial-Readiness Platform

Robert A. Rissman, PhD

Translates biomarker discoveries from genomics, proteomics, and fluid-based assays into diagnostic algorithms, trial-enrichment strategies, and precision-treatment frameworks.

Assay Standardization, Regulatory Strategy & Deployment

Timothy E. Van Meter, PhD

Carries validated biomarker panels through standardization, regulatory approval pathways, and commercial clinical deployment.

Organizational Structure

  • Steering Committee

    Four Co-Directors providing strategic leadership.

  • Scientific Advisory Board

    Domain expertise — data science, medical, ethical.

  • Core Facilities

    Biomarker Lab · Biorepository · Neurogenomics Center · Diagnostic Development.

  • Data Coordination Center

    Centralized data management, harmonization, and analytics.

  • Clinical Sites Network

    Multi-site cohorts for recruitment, sample collection, and validation.

  • Industry Collaborators

    Key technology and therapeutic partnerships for innovation and translation.

Integrated infrastructure designed for end-to-end translational impact

Four Scientific Pillars

Pillar 1

Multi-Omic Discovery

Genomic, proteomic, and lipidomic profiling for disease-specific molecular signatures across neurodegenerative and cardiometabolic conditions.

Pillar 2

Fluid Biomarker Innovation

Next-generation blood-based and CSF biomarker panels for differential diagnosis of coexisting pathologies.

Pillar 3

Neuropathological Validation

Biomarker performance verified against autopsy-confirmed diagnoses to establish neuropathological ground truth.

Pillar 4

Translational Deployment

Assay standardization, regulatory strategy, and clinical implementation for real-world diagnostic use.

Layered multi-omic data strata with fine signal traces
A luminous droplet above a grid of assay wells

Partner with us to advance the science of differential diagnosis.

Contact the consortium